Apathy associated with neurocognitive disorders: Recent progress and future directions

Alzheimer's and Dementia

Volumn 13, Issue 1, 2017, Pages 84-100

  Lanctôt, Krista L ^a,b   Agüera Ortiz, Luis ^c,d   Brodaty, Henry ^e   Francis, Paul T ^f   Geda, Yonas E ^g   Ismail, Zahinoor ^h   Marshall, Gad A ⁱ   Mortby, Moyra E ^j   Onyike, Chiadi U ^k   Padala, Prasad R ^l,m   Politis, Antonios M ⁿ   Rosenberg, Paul B ^o   Siegel, Emma ^e   Sultzer, David L ^p   Abraham, Eleenor H ^a  

^a Canada   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^d HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

^f KING'S COLLEGE LONDON   (United Kingdom)

^g MAYO CLINIC   (United States)

^h UNIVERSITY OF CALGARY   (Canada)

ⁱ MASSACHUSETTS GENERAL HOSPITAL   (United States)

^j AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

^k JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l GERIATRIC RESEARCH EDUCATION AND CLINICAL CENTER   (United States)

^m UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

ⁿ NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^o JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

^p VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

more..

Author keywords

Alzheimer's disease (AD); Apathy; Mild behavioral impairment (MBI); Neurocognitive disorders (NCD); neuropsychiatric symptoms (NPS)

Indexed keywords

AMYLOID; TAU PROTEIN;

ALZHEIMER DISEASE; APATHY; DEPRESSION; DISEASE ASSOCIATION; DISEASE SEVERITY; DISORDERS OF HIGHER CEREBRAL FUNCTION; GENETICS; HUMAN; NERVE CELL NETWORK; NEUROBIOLOGY; NEUROCHEMISTRY; NEUROIMAGING; NEUROMODULATION; NEUROPATHOLOGY; NONHUMAN; PHARMACEUTICAL CARE; PHENOMENOLOGY; PREVALENCE; PRIORITY JOURNAL; PRODROMAL SYMPTOM; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW (TOPIC); BRAIN; DIAGNOSTIC IMAGING; NEUROCOGNITIVE DISORDERS; NEUROPSYCHOLOGICAL TEST; PSYCHOLOGY;

APATHY; BRAIN; DEPRESSION; HUMANS; NEUROBIOLOGY; NEUROCOGNITIVE DISORDERS; NEUROIMAGING; NEUROPSYCHOLOGICAL TESTS;

EID: 84996773938     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2016.05.008     Document Type: Review

References (163)

1. [1] Marin, R.S., Differential diagnosis and classification of apathy. Am J Psychiatry 147 (1990), 22–30.
2. [2] Marin, R.S., Apathy: a neuropsychiatric syndrome. J Neuropsychiatry Clin Neurosci 3 (1991), 243–254.
3. [3] American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5. 2013, American Psychiatric Association, Washington, D.C.
4. [4] Ishii, S., Weintraub, N., Mervis, J.R., Apathy: a common psychiatric syndrome in the elderly. J Am Med Dir Assoc 10 (2009), 381–393.
5. [5] Robert, P., Onyike, C.U., Leentjens, A.F., Dujardin, K., Aalten, P., Starkstein, S., et al. Proposed diagnostic criteria for apathy in Alzheimer's disease and other neuropsychiatric disorders. Eur Psychiatry 24 (2009), 98–104.
6. [6] Geda, Y.E., Schneider, L.S., Gitlin, L.N., Miller, D.S., Smith, G.S., Bell, J., et al. Neuropsychiatric symptoms in Alzheimer's disease: past progress and anticipation of the future. Alzheimers Dement 9 (2013), 602–608.
7. [7] Brodaty, H., Altendorf, A., Withall, A., Sachdev, P., Do people become more apathetic as they grow older? A longitudinal study in healthy individuals. Int Psychogeriatr 22 (2010), 426–436.
8. [8] Kokmen, E., Ozsarfati, Y., Beard, C.M., O'Brien, P.C., Rocca, W.A., Impact of referral bias on clinical and epidemiological studies of Alzheimer's disease. J Clin Epidemiol 49 (1996), 79–83.
9. [9] Tsuang, D., Kukull, W., Sheppard, L., Barnhart, R.L., Peskind, E., Edland, S.D., et al. Impact of sample selection on APOE epsilon 4 allele frequency: a comparison of two Alzheimer's disease samples. J Am Geriatr Soc 44 (1996), 704–707.
10. [10] Mega, M.S., Cummings, J.L., Fiorello, T., Gornbein, J., The spectrum of behavioral changes in Alzheimer's disease. Neurology 46 (1996), 130–135.
11. [11] Hwang, T.J., Masterman, D.L., Ortiz, F., Fairbanks, L.A., Cummings, J.L., Mild cognitive impairment is associated with characteristic neuropsychiatric symptoms. Alzheimer Dis Assoc Disord 18 (2004), 17–21.
12. [12] Copeland, M.P., Daly, E., Hines, V., Mastromauro, C., Zaitchik, D., Gunther, J., et al. Psychiatric symptomatology and prodromal Alzheimer's disease. Alzheimer Dis Assoc Disord 17 (2003), 1–8.
13. [13] Lyketsos, C.G., Lopez, O., Jones, B., Fitzpatrick, A.L., Breitner, J., DeKosky, S., Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA 288 (2002), 1475–1483.
14. [14] Geda, Y.E., Roberts, R.O., Knopman, D.S., Petersen, R.C., Christianson, T.J., Pankratz, V.S., et al. Prevalence of neuropsychiatric symptoms in mild cognitive impairment and normal cognitive aging: population-based study. Arch Gen Psychiatry 65 (2008), 1193–1198.
15. [15] Palmer, K., Berger, A.K., Monastero, R., Winblad, B., Backman, L., Fratiglioni, L., Predictors of progression from mild cognitive impairment to Alzheimer disease. Neurology 68 (2007), 1596–1602.
16. [16] Mortby, M.E., Maercker, A., Forstmeier, S., Apathy: a separate syndrome from depression in dementia? A critical review. Aging Clin Exp Res 24 (2012), 305–316.
17. [17] Onyike, C.U., Sheppard, J.M., Tschanz, J.T., Norton, M.C., Green, R.C., Steinberg, M., et al. Epidemiology of apathy in older adults: the Cache County Study. Am J Geriatr Psychiatry 15 (2007), 365–375.
18. [18] Lyketsos, C.G., Steinberg, M., Tschanz, J.T., Norton, M.C., Steffens, D.C., Breitner, J.C., Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging. Am J Psychiatry 157 (2000), 708–714.
19. [19] Marin, R.S., Biedrzycki, R.C., Firinciogullari, S., Reliability and validity of the Apathy Evaluation Scale. Psychiatry Res 38 (1991), 143–162.
20. [20] Guercio, B.J., Donovan, N.J., Munro, C.E., Aghjayan, S.L., Wigman, S.E., Locascio, J.J., et al. The Apathy Evaluation Scale: A Comparison of Subject, Informant, and Clinician Report in Cognitively Normal Elderly and Mild Cognitive Impairment. J Alzheimers Dis 47 (2015), 421–432.
21. [21] Cummings, J.L., Frontal-subcortical circuits and human behavior. Arch Neurol 50 (1993), 873–880.
22. [22] Levy, R., Dubois, B., Apathy and the functional anatomy of the prefrontal cortex-basal ganglia circuits. Cereb Cortex 16 (2006), 916–928.
23. [23] Novais, F., Starkstein, S., Phenomenology of depression in Alzheimer's disease. J Alzheimers Dis 47 (2015), 845–855.
24. [24] Teng, E., Ringman, J.M., Ross, L.K., Mulnard, R.A., Dick, M.B., Bartzokis, G., et al. Diagnosing depression in Alzheimer disease with the national institute of mental health provisional criteria. Am J Geriatr Psychiatry 16 (2008), 469–477.
25. [25] Olin, J.T., Katz, I.R., Meyers, B.S., Schneider, L.S., Lebowitz, B.D., Provisional diagnostic criteria for depression of Alzheimer disease: rationale and background. Am J Geriatr Psychiatry 10 (2002), 129–141.
26. [26] Troisi, A., Pasini, A., Gori, G., Sorbi, T., Biagini, C., Aulisi, A., et al. Assessment of depression in Alzheimer's disease: symptoms, syndrome, and computed tomography findings. Dementia 4 (1993), 87–93.
27. [27] Starkstein, S.E., Petracca, G., Chemerinski, E., Kremer, J., Syndromic validity of apathy in Alzheimer's disease. Am J Psychiatry 158 (2001), 872–877.
28. [28] Drijgers, R.L., Dujardin, K., Reijnders, J.S., Defebvre, L., Leentjens, A.F., Validation of diagnostic criteria for apathy in Parkinson's disease. Parkinsonism Relat Disord 16 (2010), 656–660.
29. [29] Mulin, E., Leone, E., Dujardin, K., Delliaux, M., Leentjens, A., Nobili, F., et al. Diagnostic criteria for apathy in clinical practice. Int J Geriatr Psychiatry 26 (2011), 158–165.
30. [30] Clarke, D.E., Ko, J.Y., Kuhl, E.A., van Reekum, R., Salvador, R., Marin, R.S., Are the available apathy measures reliable and valid? A review of the psychometric evidence. J Psychosom Res 70 (2011), 73–97.
31. [31] Lueken, U., Seidl, U., Volker, L., Schweiger, E., Kruse, A., Schroder, J., Development of a short version of the Apathy Evaluation Scale specifically adapted for demented nursing home residents. Am J Geriatr Psychiatry 15 (2007), 376–385.
32. [32] Starkstein, S.E., Ingram, L., Garau, M.L., Mizrahi, R., On the overlap between apathy and depression in dementia. J Neurol Neurosurg Psychiatry 76 (2005), 1070–1074.
33. [33] Starkstein, S.E., Mayberg, H.S., Preziosi, T.J., Andrezejewski, P., Leiguarda, R., Robinson, R.G., Reliability, validity, and clinical correlates of apathy in Parkinson's disease. J Neuropsychiatry Clin Neurosci 4 (1992), 134–139.
34. [34] Robert, P.H., Clairet, S., Benoit, M., Koutaich, J., Bertogliati, C., Tible, O., et al. The apathy inventory: assessment of apathy and awareness in Alzheimer's disease, Parkinson's disease and mild cognitive impairment. Int J Geriatr Psychiatry 17 (2002), 1099–1105.
35. [35] Strauss, M.E., Sperry, S.D., An informant-based assessment of apathy in Alzheimer disease. Neuropsychiatry Neuropsychol Behav Neurol 15 (2002), 176–183.
36. [36] Sockeel, P., Dujardin, K., Devos, D., Deneve, C., Destee, A., Defebvre, L., The Lille apathy rating scale (LARS), a new instrument for detecting and quantifying apathy: validation in Parkinson's disease. J Neurol Neurosurg Psychiatry 77 (2006), 579–584.
37. [37] Radakovic, R., Abrahams, S., Developing a new apathy measurement scale: Dimensional Apathy Scale. Psychiatry Res 219 (2014), 658–663.
38. [38] Cummings, J.L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D.A., Gornbein, J., The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 44 (1994), 2308–2314.
39. [39] Kaufer, D.I., Cummings, J.L., Ketchel, P., Smith, V., MacMillan, A., Shelley, T., et al. Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. J Neuropsychiatry Clin Neurosci 12 (2000), 233–239.
40. [40] Aguera-Ortiz, L., Gil-Ruiz, N., Cruz-Orduna, I., Ramos-Garcia, I., Osorio, R.S., Valenti-Soler, M., et al. A novel rating scale for the measurement of apathy in institutionalized persons with dementia: the APADEM-NH. Am J Geriatr Psychiatry 23 (2015), 149–159.
41. [41] Jao, Y.L., Algase, D.L., Specht, J.K., Williams, K., Developing the Person-Environment Apathy Rating for persons with dementia. Aging Ment Health 20 (2016), 861–870.
42. [42] Clarke, D.E., Reekum, R., Simard, M., Streiner, D.L., Freedman, M., Conn, D., Apathy in dementia: an examination of the psychometric properties of the apathy evaluation scale. J Neuropsychiatry Clin Neurosci 19 (2007), 57–64.
43. [43] Chau, S.A., Chung, J., Herrmann, N., Eizenman, M., Lanctot, K.L., Apathy and Attentional Biases in Alzheimer's Disease. J Alz Disord 17 (2016), 837–846.
44. [44] David, R., Mulin, E., Friedman, L., Le Duff, F., Cygankiewicz, E., Deschaux, O., et al. Decreased daytime motor activity associated with apathy in Alzheimer disease: an actigraphic study. Am J Geriatr Psychiatry 20 (2012), 806–814.
45. [45] Kuhlmei, A., Walther, B., Becker, T., Muller, U., Nikolaus, T., Actigraphic daytime activity is reduced in patients with cognitive impairment and apathy. Eur Psychiatry 28 (2013), 94–97.
46. [46] Valembois, L., Oasi, C., Pariel, S., Jarzebowski, W., Lafuente-Lafuente, C., Belmin, J., Wrist Actigraphy: A Simple Way to Record Motor Activity in Elderly Patients with Dementia and Apathy or Aberrant Motor Behavior. J Nutr Health Aging 19 (2015), 759–764.
47. [47] Tung, J.Y., Rose, R.V., Gammada, E., Lam, I., Roy, E.A., Black, S.E., et al. Measuring life space in older adults with mild-to-moderate Alzheimer's disease using mobile phone GPS. Gerontology 60 (2014), 154–162.
48. [48] Pink, A., Stokin, G.B., Bartley, M.M., Roberts, R.O., Sochor, O., Machulda, M.M., et al. Neuropsychiatric symptoms, APOE epsilon4, and the risk of incident dementia: a population-based study. Neurology 84 (2015), 935–943.
49. [49] Duara, R., Loewenstein, D.A., Greig, M.T., Potter, E., Barker, W., Raj, A., et al. Pre-MCI and MCI: neuropsychological, clinical, and imaging features and progression rates. Am J Geriatr Psychiatry 19 (2011), 951–960.
50. [50] Gallassi, R., Oppi, F., Poda, R., Scortichini, S., Stanzani Maserati, M., Marano, G., et al. Are subjective cognitive complaints a risk factor for dementia?. Neurol Sci 31 (2010), 327–336.
51. [51] Geda, Y.E., Roberts, R.O., Mielke, M.M., Knopman, D.S., Christianson, T.J., Pankratz, V.S., et al. Baseline neuropsychiatric symptoms and the risk of incident mild cognitive impairment: a population-based study. Am J Psychiatry 171 (2014), 572–581.
52. [52] Brodaty, H.H.M., Draper, B., Reppermund, S., Kochan, N.A., Slavin, M.J., Trollor, J.N., et al. Neuropsychiatric Symptoms in Older People with and without Cognitive Impairment. J Alzheimers Dis 31 (2012), 411–420.
53. [53] Seligman, S.C., Kamath, V., Giovannetti, T., Arnold, S.E., Moberg, P.J., Olfaction and apathy in Alzheimer's disease, mild cognitive impairment, and healthy older adults. Aging Ment Health 17 (2013), 564–570.
54. [54] Clarke, D.E., Ko, J.Y., Lyketsos, C., Rebok, G.W., Eaton, W.W., Apathy and cognitive and functional decline in community-dwelling older adults: results from the Baltimore ECA longitudinal study. Int Psychogeriatr 22 (2010), 819–829.
55. [55] Rog, L.A., Park, L.Q., Harvey, D.J., Huang, C.J., Mackin, S., Farias, S.T., The independent contributions of cognitive impairment and neuropsychiatric symptoms to everyday function in older adults. Clin Neuropsychol 28 (2014), 215–236.
56. [56] Wadsworth, L.P., Lorius, N., Donovan, N.J., Locascio, J.J., Rentz, D.M., Johnson, K.A., et al. Neuropsychiatric symptoms and global functional impairment along the Alzheimer's continuum. Dement Geriatr Cogn Disord 34 (2012), 96–111.
57. [57] Bouwens, S.F., van Heugten, C.M., Aalten, P., Wolfs, C.A., Baarends, E.M., van Menxel, D.A., et al. Relationship between measures of dementia severity and observation of daily life functioning as measured with the Assessment of Motor and Process Skills (AMPS). Dement Geriatr Cogn Disord 25 (2008), 81–87.
58. [58] Aalten, P., de Vugt, M.E., Jaspers, N., Jolles, J., Verhey, F.R., The course of neuropsychiatric symptoms in dementia. Part I: findings from the two-year longitudinal Maasbed study. Int J Geriatr Psychiatry 20 (2005), 523–530.
59. [59] Steinberg, M., Tschanz, J.T., Corcoran, C., Steffens, D.C., Norton, M.C., Lyketsos, C.G., et al. The persistence of neuropsychiatric symptoms in dementia: the Cache County Study. Int J Geriatr Psychiatry 19 (2004), 19–26.
60. [60] Galvin, J.E., Duda, J.E., Kaufer, D.I., Lippa, C.F., Taylor, A., Zarit, S.H., Lewy body dementia: caregiver burden and unmet needs. Alzheimer Dis Assoc Disord 24 (2010), 177–181.
61. [61] Rascovsky, K., Hodges, J.R., Knopman, D., Mendez, M.F., Kramer, J.H., Neuhaus, J., et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 134 (2011), 2456–2477.
62. [62] Golbe, L.I., Progressive supranuclear palsy. Semin Neurol 34 (2014), 151–159.
63. [63] Sperling, R.A., Aisen, P.S., Beckett, L.A., Bennett, D.A., Craft, S., Fagan, A.M., et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7 (2011), 280–292.
64. [64] Ismail, Z., Smith, E.E., Geda, Y., Sultzer, D., Brodaty, H., Smith, G., et al. Neuropsychiatric symptoms as early manifestations of emergent dementia: Provisional diagnostic criteria for mild behavioral impairment. Alzheimers Dement 12 (2016), 195–202.
65. [65] Forstl, H., Burns, A., Levy, R., Cairns, N., Luthert, P., Lantos, P., Neuropathological correlates of behavioural disturbance in confirmed Alzheimer's disease. Br J Psychiatry 163 (1993), 364–368.
66. [66] Marshall, G.A., Fairbanks, L.A., Tekin, S., Vinters, H.V., Cummings, J.L., Neuropathologic correlates of apathy in Alzheimer's disease. Dement Geriatr Cogn Disord 21 (2006), 144–147.
67. [67] Tekin, S., Mega, M.S., Masterman, D.M., Chow, T., Garakian, J., Vinters, H.V., et al. Orbitofrontal and anterior cingulate cortex neurofibrillary tangle burden is associated with agitation in Alzheimer disease. Ann Neurol 49 (2001), 355–361.
68. [68] Mori, T., Shimada, H., Shinotoh, H., Hirano, S., Eguchi, Y., Yamada, M., et al. Apathy correlates with prefrontal amyloid beta deposition in Alzheimer's disease. J Neurol Neurosurg Psychiatry 85 (2014), 449–455.
69. [69] Marshall, G.A., Donovan, N.J., Lorius, N., Gidicsin, C.M., Maye, J., Pepin, L.C., et al. Apathy is associated with increased amyloid burden in mild cognitive impairment. J Neuropsychiatry Clin Neurosci 25 (2013), 302–307.
70. [70] Skogseth, R., Mulugeta, E., Jones, E., Ballard, C., Rongve, A., Nore, S., et al. Neuropsychiatric correlates of cerebrospinal fluid biomarkers in Alzheimer's disease. Dement Geriatr Cogn Disord 25 (2008), 559–563.
71. [71] Donovan, N.J., Wadsworth, L.P., Lorius, N., Locascio, J.J., Rentz, D.M., Johnson, K.A., et al. Regional cortical thinning predicts worsening apathy and hallucinations across the Alzheimer disease spectrum. Am J Geriatr Psychiatry 22 (2014), 1168–1179.
72. [72] Vermeiren, Y., Van Dam, D., Aerts, T., Engelborghs, S., De Deyn, P.P., Monoaminergic neurotransmitter alterations in postmortem brain regions of depressed and aggressive patients with Alzheimer's disease. Neurobiol Aging 35 (2014), 2691–2700.
73. [73] David, R., Koulibaly, M., Benoit, M., Garcia, R., Caci, H., Darcourt, J., et al. Striatal dopamine transporter levels correlate with apathy in neurodegenerative diseases A SPECT study with partial volume effect correction. Clin Neurol Neurosurg 110 (2008), 19–24.
74. [74] Sultzer, D., Melrose, R., Campa, O.M., Achamallah, N., Harwood, D.G., Brody, A.L., et al. Cholinergic receptor imaging in Alzheimer's disease: method and early results. Am J Geriatr Psychiatry 18 (2010), S71–S72.
75. [75] Lanctot, K.L., Herrmann, N., Rothenburg, L., Eryavec, G., Behavioral correlates of GABAergic disruption in Alzheimer's disease. Int Psychogeriatr 19 (2007), 151–158.
76. [76] Lanctot, K.L., Herrmann, N., Black, S.E., Ryan, M., Rothenburg, L.S., Liu, B.A., et al. Apathy associated with Alzheimer disease: use of dextroamphetamine challenge. Am J Geriatr Psychiatry 16 (2008), 551–557.
77. [77] Feldman, H., Gauthier, S., Hecker, J., Vellas, B., Subbiah, P., Whalen, E., A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 57 (2001), 613–620.
78. [78] Mitchell, R.A., Herrmann, N., Lanctot, K.L., The role of dopamine in symptoms and treatment of apathy in Alzheimer's disease. CNS Neurosci Ther 17 (2011), 411–427.
79. [79] Rosenberg, P.B., Lanctot, K.L., Drye, L.T., Herrmann, N., Scherer, R.W., Bachman, D.L., et al. Safety and efficacy of methylphenidate for apathy in Alzheimer's disease: a randomized, placebo-controlled trial. J Clin Psychiatry 74 (2013), 810–816.
80. [80] Schneider, F., Baldauf, K., Wetzel, W., Reymann, K.G., Effects of methylphenidate on the behavior of male 5xFAD mice. Pharmacol Biochem Behav 128 (2015), 68–77.
81. [81] Rochat, L., Van der Linden, M., Renaud, O., Epiney, J.B., Michel, P., Sztajzel, R., et al. Poor reward sensitivity and apathy after stroke: implication of basal ganglia. Neurology 81 (2013), 1674–1680.
82. [82] Pagonabarraga, J., Kulisevsky, J., Strafella, A.P., Krack, P., Apathy in Parkinson's disease: clinical features, neural substrates, diagnosis, and treatment. Lancet Neurol 14 (2015), 518–531.
83. [83] Williams, N.R., Hopkins, T.R., Short, E.B., Sahlem, G.L., Snipes, J., Revuelta, G.J., et al. Reward circuit DBS improves Parkinson's gait along with severe depression and OCD. Neurocase 22 (2016), 201–204.
84. [84] Kim, H.J., Jeon, B.S., Paek, S.H., Nonmotor Symptoms and Subthalamic Deep Brain Stimulation in Parkinson's Disease. J Mov Disord 8 (2015), 83–91.
85. [85] Adam, R., Leff, A., Sinha, N., Turner, C., Bays, P., Draganski, B., et al. Dopamine reverses reward insensitivity in apathy following globus pallidus lesions. Cortex 49 (2013), 1292–1303.
86. [86] Kohno, N., Abe, S., Toyoda, G., Oguro, H., Bokura, H., Yamaguchi, S., Successful treatment of post-stroke apathy by the dopamine receptor agonist ropinirole. J Clin Neurosci 17 (2010), 804–806.
87. [87] Zubenko, G.S., Marquis, J.K., Volicer, L., Direnfeld, L.K., Langlais, P.J., Nixon, R.A., Cerebrospinal fluid levels of angiotensin-converting enzyme, acetylcholinesterase, and dopamine metabolites in dementia associated with Alzheimer's disease and Parkinson's disease: a correlative study. Biol Psychiatry 21 (1986), 1365–1381.
88. [88] Umegaki, H., Ikari, H., Nakahata, H., Yoshimura, J., Endo, H., Yamamoto, T., et al. Low plasma epinephrine in elderly female subjects of dementia of Alzheimer type. Brain Res 858 (2000), 67–70.
89. [89] Liu, L., Li, Q., Li, N., Ling, J., Liu, R., Wang, Y., et al. Simultaneous determination of catecholamines and their metabolites related to Alzheimer's disease in human urine. J Sep Sci 34 (2011), 1198–1204.
90. [90] Duarte, S.T., Ortez, C., Perez, A., Artuch, R., Garcia-Cazorla, A., Analysis of synaptic proteins in the cerebrospinal fluid as a new tool in the study of inborn errors of neurotransmission. J Inherit Metab Dis 34 (2011), 523–528.
91. [91] Theleritis, C., Politis, A., Siarkos, K., Lyketsos, C.G., A review of neuroimaging findings of apathy in Alzheimer's disease. Int Psychogeriatr 26 (2014), 195–207.
92. [92] Lanctot, K.L., Moosa, S., Herrmann, N., Leibovitch, F.S., Rothenburg, L., Cotter, A., et al. A SPECT study of apathy in Alzheimer's disease. Dement Geriatr Cogn Disord 24 (2007), 65–72.
93. [93] Marshall, G.A., Monserratt, L., Harwood, D., Mandelkern, M., Cummings, J.L., Sultzer, D.L., Positron emission tomography metabolic correlates of apathy in Alzheimer disease. Arch Neurol 64 (2007), 1015–1020.
94. [94] Moon, Y., Moon, W.J., Kim, H., Han, S.H., Regional atrophy of the insular cortex is associated with neuropsychiatric symptoms in Alzheimer's disease patients. Eur Neurol 71 (2014), 223–229.
95. [95] Stanton, B.R., Leigh, P.N., Howard, R.J., Barker, G.J., Brown, R.G., Behavioural and emotional symptoms of apathy are associated with distinct patterns of brain atrophy in neurodegenerative disorders. J Neurol 260 (2013), 2481–2490.
96. [96] Sultzer, D.L., Melrose, R.J., Narvaez, T.A., Veliz, J.V., Harwood, D.G., Juarez, K.O., et al. Apathy and regional cholinergic receptor binding in Alzheimer's disease: 2-FA PET imaging. Am J Geriatr Psychiatry 24 (2016), S135–S136.
97. [97] Hahn, C., Lim, H.K., Won, W.Y., Ahn, K.J., Jung, W.S., Lee, C.U., Apathy and white matter integrity in Alzheimer's disease: a whole brain analysis with tract-based spatial statistics. PLoS One, 8, 2013, e53493.
98. [98] Moon, Y., Kim, H., Ok Kim, J., Han, S.H., Vascular factors are associated with the severity of the neuropsychiatric symptoms in Alzheimer's disease. Int J Neurosci 124 (2014), 512–517.
99. [99] Guercio, B.J., Donovan, N.J., Ward, A., Schultz, A., Lorius, N., Amariglio, R.E., et al. Apathy is associated with lower inferior temporal cortical thickness in mild cognitive impairment and normal elderly individuals. J Neuropsychiatry Clin Neurosci 27 (2015), e22–e27.
100. [100] Delrieu, J., Desmidt, T., Camus, V., Sourdet, S., Boutoleau-Bretonniere, C., Mullin, E., et al. Apathy as a feature of prodromal Alzheimer's disease: an FDG-PET ADNI study. Int J Geriatr Psychiatry 30 (2015), 470–477.
101. [101] Torso, M., Serra, L., Giulietti, G., Spano, B., Tuzzi, E., Koch, G., et al. Strategic lesions in the anterior thalamic radiation and apathy in early Alzheimer's disease. PLoS One, 10, 2015, e0124998.
102. [102] Donovan, N.J., Hsu, D.C., Dagley, A.S., Schultz, A.P., Amariglio, R.E., Mormino, E.C., et al. Depressive Symptoms and Biomarkers of Alzheimer's Disease in Cognitively Normal Older Adults. J Alzheimers Dis 46 (2015), 63–73.
103. [103] Robert, P.H., Darcourt, G., Koulibaly, M.P., Clairet, S., Benoit, M., Garcia, R., et al. Lack of initiative and interest in Alzheimer's disease: a single photon emission computed tomography study. Eur J Neurol 13 (2006), 729–735.
104. [104] Benoit, M., Clairet, S., Koulibaly, P.M., Darcourt, J., Robert, P.H., Brain perfusion correlates of the apathy inventory dimensions of Alzheimer's disease. Int J Geriatr Psychiatry 19 (2004), 864–869.
105. [105] Sultzer, D.L., Leskin, L.P., Jacobs, Z.M., Melrose, R.J., Harwood, D.G., Naarvaez, T.A., et al. Cognitive, behavioral, and emotional domains of apathy in Alzheimer's disease: clinical and neurobiological features. Am J Geriatr Psychiatry 21 (2013), S144–S145.
106. [106] Agüera-Ortiz. Hernandez-Tamames J, Martinez-Martin P, Cruz-Orduña I, Pajares G, López-Alvarez J, Osorio RS, Sanz M, Olazarán-Rodriguez J. Structural correlates of apathy in Alzheimer's diseas: a multimodal MRI study (in review).
107. [107] Apostolova, L.G., Akopyan, G.G., Partiali, N., Steiner, C.A., Dutton, R.A., Hayashi, K.M., et al. Structural correlates of apathy in Alzheimer's disease. Dement Geriatr Cogn Disord 24 (2007), 91–97.
108. [108] Holthoff, V.A., Beuthien-Baumann, B., Kalbe, E., Ludecke, S., Lenz, O., Zundorf, G., et al. Regional cerebral metabolism in early Alzheimer's disease with clinically significant apathy or depression. Biol Psychiatry 57 (2005), 412–421.
109. [109] Kang, J.Y., Lee, J.S., Kang, H., Lee, H.W., Kim, Y.K., Jeon, H.J., et al. Regional cerebral blood flow abnormalities associated with apathy and depression in Alzheimer disease. Alzheimer Dis Assoc Disord 26 (2012), 217–224.
110. [110] Kim, J.W., Lee, D.Y., Choo, I.H., Seo, E.H., Kim, S.G., Park, S.Y., et al. Microstructural alteration of the anterior cingulum is associated with apathy in Alzheimer disease. Am J Geriatr Psychiatry 19 (2011), 644–653.
111. [111] Starkstein, S.E., Mizrahi, R., Capizzano, A.A., Acion, L., Brockman, S., Power, B.D., Neuroimaging correlates of apathy and depression in Alzheimer's disease. J Neuropsychiatry Clin Neurosci 21 (2009), 259–265.
112. [112] Munro, C.E., Donovan, N.J., Guercio, B.J., Wigman, S.E., Schultz, A.P., Amariglio, R.E., et al. Neuropsychiatric Symptoms and Functional Connectivity in Mild Cognitive Impairment. J Alzheimers Dis 46 (2015), 727–735.
113. [113] Monastero, R., Mariani, E., Camarda, C., Ingegni, T., Averna, M.R., Senin, U., et al. Association between apolipoprotein E epsilon4 allele and apathy in probable Alzheimer's disease. Acta Psychiatr Scand 113 (2006), 59–63.
114. [114] D'Onofrio, G., Panza, F., Seripa, D., Sancarlo, D., Paris, F., Cascavilla, L., et al. The APOE polymorphism in Alzheimer's disease patients with neuropsychiatric symptoms and syndromes. Int J Geriatr Psychiatry 26 (2011), 1062–1070.
115. [115] Del Prete, M., Spaccavento, S., Craca, A., Fiore, P., Angelelli, P., Neuropsychiatric symptoms and the APOE genotype in Alzheimer's disease. Neurol Sci 30 (2009), 367–373.
116. [116] Borroni, B., Grassi, M., Agosti, C., Costanzi, C., Archetti, S., Franzoni, S., et al. Genetic correlates of behavioral endophenotypes in Alzheimer disease: role of COMT, 5-HTTLPR and APOE polymorphisms. Neurobiol Aging 27 (2006), 1595–1603.
117. [117] van der Flier, W.M., Staekenborg, S., Pijnenburg, Y.A., Gillissen, F., Romkes, R., Kok, A., et al. Apolipoprotein E genotype influences presence and severity of delusions and aggressive behavior in Alzheimer disease. Dement Geriatr Cogn Disord 23 (2007), 42–46.
118. [118] Levy, M.L., Cummings, J.L., Fairbanks, L.A., Sultzer, D.L., Small, G.W., Apolipoprotein E genotype and noncognitive symptoms in Alzheimer's disease. Biol Psychiatry 45 (1999), 422–425.
119. [119] David, R., Friedman, L., Mulin, E., Noda, A., Le Duff, F., Kennedy, Q., et al. Lack of Association Between COMT Polymorphisms and Apathy in Alzheimer's Disease. J Alzheimers Dis 27 (2011), 155–161.
120. [120] Mitaki, S., Isomura, M., Maniwa, K., Yamasaki, M., Nagai, A., Nabika, T., et al. Apathy is associated with a single-nucleotide polymorphism in a dopamine-related gene. Neurosci Lett 549 (2013), 87–91.
121. [121] Somme, J.H., Molano Salazar, A., Gonzalez, A., Tijero, B., Berganzo, K., Lezcano, E., et al. Cognitive and behavioral symptoms in Parkinson's disease patients with the G2019S and R1441G mutations of the LRRK2 gene. Parkinsonism Relat Disord 21 (2015), 494–499.
122. [122] Brown, C.A., Campbell, M.C., Karimi, M., Tabbal, S.D., Loftin, S.K., Tian, L.L., et al. Dopamine pathway loss in nucleus accumbens and ventral tegmental area predicts apathetic behavior in MPTP-lesioned monkeys. Exp Neurol 236 (2012), 190–197.
123. [123] Tian, L., Xia, Y., Flores, H.P., Campbell, M.C., Moerlein, S.M., Perlmutter, J.S., Neuroimaging Analysis of the Dopamine Basis for Apathetic Behaviors in an MPTP-Lesioned Primate Model. PLoS One, 10, 2015, e0132064.
124. [124] Favier, M., Duran, T., Carcenac, C., Drui, G., Savasta, M., Carnicella, S., Pramipexole reverses Parkinson's disease-related motivational deficits in rats. Mov Disord 29 (2014), 912–920.
125. [125] Slattery, D.A., Cryan, J.F., The ups and downs of modelling mood disorders in rodents. ILAR J 55 (2014), 297–309.
126. [126] Filali, M., Lalonde, R., Rivest, S., Anomalies in social behaviors and exploratory activities in an APPswe/PS1 mouse model of Alzheimer's disease. Physiol Behav 104 (2011), 880–885.
127. [127] Schneider, F., Baldauf, K., Wetzel, W., Reymann, K.G., Behavioral and EEG changes in male 5xFAD mice. Physiol Behav 135 (2014), 25–33.
128. [128] Berman, K., Brodaty, H., Withall, A., Seeher, K., Pharmacologic treatment of apathy in dementia. Am J Geriatr Psychiatry 20 (2012), 104–122.
129. [129] Leontjevas, R., Teerenstra, S., Smalbrugge, M., Vernooij-Dassen, M.J., Bohlmeijer, E.T., Gerritsen, D.L., et al. More insight into the concept of apathy: a multidisciplinary depression management program has different effects on depressive symptoms and apathy in nursing homes. Int Psychogeriatr 25 (2013), 1941–1952.
130. [130] Holmes, C., Wilkinson, D., Dean, C., Vethanayagam, S., Olivieri, S., Langley, A., et al. The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology 63 (2004), 214–219.
131. [131] Waldemar, G., Gauthier, S., Jones, R., Wilkinson, D., Cummings, J., Lopez, O., et al. Effect of donepezil on emergence of apathy in mild to moderate Alzheimer's disease. Int J Geriatr Psychiatry 26 (2011), 150–157.
132. [132] Herrmann, N., Rabheru, K., Wang, J., Binder, C., Galantamine treatment of problematic behavior in Alzheimer disease: post-hoc analysis of pooled data from three large trials. Am J Geriatr Psychiatry 13 (2005), 527–534.
133. [133] Brodaty, H., Woodward, M., Boundy, K., Barnes, N., Allen, G., NATURE Investigators. A naturalistic study of galantamine for Alzheimer's disease. CNS Drugs 20 (2006), 935–943.
134. [134] Cummings, J.L., Koumaras, B., Chen, M., Mirski, D., Rivastigmine Nursing Home Study Team. Effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe probable Alzheimer's disease: a 26-week, multicenter, open-label study. Am J Geriatr Pharmacother 3 (2005), 137–148.
135. [135] Winblad, B., Poritis, N., Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry 14 (1999), 135–146.
136. [136] Kaufer, D., Cummings, J.L., Christine, D., Differential neuropsychiatric symptom responses to tacrine in Alzheimer's disease: relationship to dementia severity. J Neuropsychiatry Clin Neurosci 10 (1998), 55–63.
137. [137] Howard, R., McShane, R., Lindesay, J., Ritchie, C., Baldwin, A., Barber, R., et al. Donepezil and memantine for moderate-to-severe Alzheimer's disease. N Engl J Med 366 (2012), 893–903.
138. [138] Zhang, N., Wei, C., Du, H., Shi, F.D., Cheng, Y., The Effect of Memantine on Cognitive Function and Behavioral and Psychological Symptoms in Mild-to-Moderate Alzheimer's Disease Patients. Dement Geriatr Cogn Disord 40 (2015), 85–93.
139. [139] Gerrard, P., Malcolm, R., Mechanisms of modafinil: A review of current research. Neuropsychiatr Dis Treat 3 (2007), 349–364.
140. [140] Padala, P.R., Burke, W.J., Bhatia, S.C., Modafinil therapy for apathy in an elderly patient. Ann Pharmacother 41 (2007), 346–349.
141. [141] Camargos, E.F., Quintas, J.L., Apathy syndrome treated successfully with modafinil. BMJ Case Rep, 2011, 2011.
142. [142] Frakey, L.L., Salloway, S., Buelow, M., Malloy, P., A randomized, double-blind, placebo-controlled trial of modafinil for the treatment of apathy in individuals with mild-to-moderate Alzheimer's disease. J Clin Psychiatry 73 (2012), 796–801.
143. [143] Galynker, I., Ieronimo, C., Miner, C., Rosenblum, J., Vilkas, N., Rosenthal, R., Methylphenidate treatment of negative symptoms in patients with dementia. J Neuropsychiatry Clin Neurosci 9 (1997), 231–239.
144. [144] Padala, P.R., Burke, W.J., Shostrom, V.K., Bhatia, S.C., Wengel, S.P., Potter, J.F., et al. Methylphenidate for apathy and functional status in dementia of the Alzheimer type. Am J Geriatr Psychiatry 18 (2010), 371–374.
145. [145] Maletta, G.J., Winegarden, T., Reversal of Anorexia by Methylphenidate in Apathetic, Severely Demented Nursing Home Patients. Am J Geriatr Psychiatry 1 (1992), 234–243.
146. [146] Herrmann, N., Rothenburg, L.S., Black, S.E., Ryan, M., Liu, B.A., Busto, U.E., et al. Methylphenidate for the treatment of apathy in Alzheimer disease: prediction of response using dextroamphetamine challenge. J Clin Psychopharmacol 28 (2008), 296–301.
147. [147] Robinson, R.G., Jorge, R.E., Clarence-Smith, K., Starkstein, S., Double-blind treatment of apathy in patients with poststroke depression using nefiracetam. J Neuropsychiatry Clin Neurosci 21 (2009), 144–151.
148. [148] George, M.S., Wassermann, E.M., Williams, W.A., Callahan, A., Ketter, T.A., Basser, P., et al. Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression. Neuroreport 6 (1995), 1853–1856.
149. [149] Maeda, F., Keenan, J.P., Tormos, J.M., Topka, H., Pascual-Leone, A., Modulation of corticospinal excitability by repetitive transcranial magnetic stimulation. Clin Neurophysiol 111 (2000), 800–805.
150. [150] Wassermann, E.M., Risk and safety of repetitive transcranial magnetic stimulation: report and suggested guidelines from the International Workshop on the Safety of Repetitive Transcranial Magnetic Stimulation, June 5-7, 1996. Electroencephalogr Clin Neurophysiol 108 (1998), 1–16.
151. [151] Padala. PR, Vannucci M. Repetitive Transcranial Magnetic Stimulation for Apathy in Alzheimer's Dementia. In: ClincialTrials.gov [Internet]. Central Arkansas Veterans Healthcare System. 2015 [2015 Dec 16]. Available from: https://www.nlm.nih.gov/services/ctcite.html. NLM Identifier: NCT02190084.
152. [152] Suemoto, C.K., Apolinario, D., Nakamura-Palacios, E.M., Lopes, L., Leite, R.E., Sales, M.C., et al. Effects of a non-focal plasticity protocol on apathy in moderate Alzheimer's disease: a randomized, double-blind, sham-controlled trial. Brain Stimul 7 (2014), 308–313.
153. [153] Hsu, W.Y., Ku, Y., Zanto, T.P., Gazzaley, A., Effects of noninvasive brain stimulation on cognitive function in healthy aging and Alzheimer's disease: a systematic review and meta-analysis. Neurobiol Aging 36 (2015), 2348–2359.
154. [154] Liao, X., Li, G., Wang, A., Liu, T., Feng, S., Guo, Z., et al. Repetitive Transcranial Magnetic Stimulation as an Alternative Therapy for Cognitive Impairment in Alzheimer's Disease: A Meta-Analysis. J Alzheimers Dis 48 (2015), 463–472.
155. [155] Drumond Marra, H.L., Myczkowski, M.L., Maia Memoria, C., Arnaut, D., Leite Ribeiro, P., Sardinha Mansur, C.G., et al. Transcranial Magnetic Stimulation to Address Mild Cognitive Impairment in the Elderly: A Randomized Controlled Study. Behav Neurol, 2015, 2015, 287843.
156. [156] Brodaty, H., Burns, K., Nonpharmacological management of apathy in dementia: a systematic review. Am J Geriatr Psychiatry 20 (2012), 549–564.
157. [157] Kolanowski, A., Litaker, M., Buettner, L., Moeller, J., Costa, P.T. Jr., A randomized clinical trial of theory-based activities for the behavioral symptoms of dementia in nursing home residents. J Am Geriatr Soc 59 (2011), 1032–1041.
158. [158] Treusch, Y., Majic, T., Page, J., Gutzmann, H., Heinz, A., Rapp, M.A., Apathy in nursing home residents with dementia: results from a cluster-randomized controlled trial. Eur Psychiatry 30 (2015), 251–257.
159. [159] Ferrero-Arias, J., Goni-Imizcoz, M., Gonzalez-Bernal, J., Lara-Ortega, F., da Silva-Gonzalez, A., Diez-Lopez, M., The efficacy of nonpharmacological treatment for dementia-related apathy. Alzheimer Dis Assoc Disord 25 (2011), 213–219.
160. [160] Hsieh, C.J., Chang, C., SU, S.F., Hsiao, Y.L., Shih, Y.W., Han, W.H., et al. Reminiscence Group Therapy on Depression and Apathy in Nursing Home Residents With Mild-to-moderate Dementia. J Exp Clin Med 2 (2010), 72–78.
161. [161] Lam, L.C., Lui, V.W., Luk, D.N., Chau, R., So, C., Poon, V., et al. Effectiveness of an individualized functional training program on affective disturbances and functional skills in mild and moderate dementia–a randomized control trial. Int J Geriatr Psychiatry 25 (2010), 133–141.
162. [162] Leone, E., Deudon, A., Bauchet, M., Laye, M., Bordone, N., Lee, J.H., et al. Management of apathy in nursing homes using a teaching program for care staff: the STIM-EHPAD study. Int J Geriatr Psychiatry 28 (2013), 383–392.
163. [163] Kiresuk, T.J., Sherman, R.E., Goal attainment scaling: A general method for evaluating comprehensive community mental health programs. Community Ment Health J 4 (1968), 443–453.